Patents Assigned to Coda Therapeutics, Inc.
  • FORMULATIONS COMPRISING ANTISENSE NUCLEOTIDES TO CONNEXINS
    Publication number: 20130079388
    Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
    Type: Application
    Filed: November 19, 2012
    Publication date: March 28, 2013
    Applicant: CODA THERAPEUTICS, INC.
    Inventor: CODA THERAPEUTICS, INC.
  • Formulations comprising antisense nucleotides to connexins
    Patent number: 8314074
    Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: November 20, 2012
    Assignee: Coda Therapeutics, Inc.
    Inventors: David Laurence Becker, Colin Richard Green
  • Methods and compositions for wound healing
    Patent number: 8247384
    Abstract: Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: August 21, 2012
    Assignee: CoDa Therapeutics, Inc.
    Inventors: Colin R. Green, Bradford J. Duft, David L. Becker
  • Antisense compounds targeted to connexins and methods of use thereof
    Patent number: 8034789
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: October 11, 2011
    Assignee: CoDa Therapeutics, Inc.
    Inventors: Wilda Laux, Colin Green
  • Formulations comprising antisense nucleotides to connexins
    Patent number: 7919474
    Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: April 5, 2011
    Assignee: CoDa Therapeutics, Inc.
    Inventors: Richard Colin Green, David Laurence Becker
  • Formulations comprising antisense nucleotides to connexins
    Patent number: 7902164
    Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: March 8, 2011
    Assignee: Coda Therapeutics, Inc.
    Inventors: Richard Colin Green, David Laurence Becker
  • Formulations comprising antisense nucleotides to connexins
    Patent number: 7879811
    Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: February 1, 2011
    Assignee: Coda Therapeutics, Inc.
    Inventors: Richard Colin Green, David Laurence Becker
  • IMPAIRED WOUND HEALING COMPOSITIONS AND TREATMENTS
    Publication number: 20100279921
    Abstract: Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for therapeutic use including uses for the promotion and/or improvement of wounds and wound healing and/or tissue repair.
    Type: Application
    Filed: December 11, 2008
    Publication date: November 4, 2010
    Applicant: CoDa Therapeutics, Inc.
    Inventor: Bradford James Duft